Evidence map›Paper›PMID 30791698›Full record

SynthesisCanadian journal of psychiatry. Revue canadienne de psychiatrie2019

Treatment Recommendations for Tardive Dyskinesia.

Lucia Ricciardi, Tamara Pringsheim, Thomas R E Barnes, Davide Martino, David Gardner, Gary Remington, Donald Addington, Francesca Morgante, Norman Poole, Alan Carson and 1 more

Open access · bronzeAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Clinical practice guidelines for the treatment of tardive dyskinesia in Europe: A descriptive review.European psychiatry : the journal of the Association of European Psychiatrists · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. Current neuropharmacology · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Lucia Ricciardi1 Neurosciences Research Centre, Molecular and Clinical Sciences Institute, St George's University of London, London, UK.
Tamara Pringsheim2 Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Thomas R E Barnes3 The Center for Psychiatry, Imperial College London, London, UK.
Davide Martino4 Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
David Gardner5 Department of Psychiatry and Pharmacy, Dalhousie University, Halifax, Nova Scotia, Canada.
Gary Remington6 Schizophrenia Division, Departments of Psychiatry and Psychological Clinical Science, Centre for Addiction and Mental Health (CAMH), University of Toronto, Toronto, Ontario, Canada.
Donald Addington7 Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.
Francesca Morgante1 Neurosciences Research Centre, Molecular and Clinical Sciences Institute, St George's University of London, London, UK.
Norman Poole8 Department of Neuropsychiatry, King's College London, London, UK.
Alan Carson9 Division of Psychiatry, University of Edinburgh, Edinburgh, UK.
Mark Edwards1 Neurosciences Research Centre, Molecular and Clinical Sciences Institute, St George's University of London, London, UK.
St George's, University of London · GBUniversity of Calgary · CADalhousie University · CAImperial College London · GBKing's College London · GBUniversity of Edinburgh · GBUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTardive dyskinesia is a movement disorder characterised by irregular, stereotyped, and choreiform movements associated with the use of antipsychotic medication. We aim to provide recommendations on the treatment of tardive dyskinesia.

methodsWe performed a systematic review of studies of the treatment of tardive dyskinesia. Studies were rated for methodological quality using the American Academy of Neurology Risk of Bias Classification system. Overall level of evidence classifications and grades of recommendation were made using the Scottish Intercollegiate Guidelines Network framework.

resultsPreventing tardive dyskinesia is of primary importance, and clinicians should follow best practice for prescribing antipsychotic medication, including limiting the prescription for specific indications, using the minimum effective dose, and minimising the duration of therapy. The first-line management of tardive dyskinesia is the withdrawal of antipsychotic medication if clinically feasible. Yet, for many patients with serious mental illness, the discontinuation of antipsychotics is not possible due to disease relapse. Switching from a first-generation to a second-generation antipsychotic with a lower D2 affinity, such as clozapine or quetiapine, may be effective in reducing tardive dyskinesia symptoms. The strongest evidence for a suitable co-intervention to treat tardive dyskinesia comes from tests with the new VMAT inhibitors, deutetrabenazine and valbenazine. These medications have not been approved for use in Canada.

conclusionData on tardive dyskinesia treatment are limited, and the best management strategy remains prevention. More long-term safety and efficacy data are needed for deutetrabenazine and valbenazine, and their routine availability to patients outside of the USA remains in question.

Indexed as

Adrenergic Uptake InhibitorsAntipsychotic AgentsHumansTardive DyskinesiaTetrabenazineValineAdrenergic Uptake InhibitorsAntipsychotic AgentsdeutetrabenazineTetrabenazinevalbenazineValineantipsychoticsevidence-based medicinetardive dyskinesia

Identifiers

PMID30791698
PMCPMC6591749
OpenAlexW2915150792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.